Alnylam Pharmaceuticals News

Dicerna Pharmaceuticals, Inc. , an RNA interference company developing novel therapeutics utilizing proprietary Dicer Substrate Technology , today announced a second closing of its Series A financing, receiving ...

Massachusetts Attorney General Martha Coakley's office said it will receive just over $9.2 million from Bristol-Myers Squibb Co.

CAMBRIDGE, Mass. - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that the Glover patent , which is exclusively licensed to Alnylam from Cancer Research Technology Limited ...

LONDON, July 11 Silence-Therapeutics LONDON , /PRNewswire/ -- Silence Therapeutics plc , a leading European RNA interference focused biotechnology company, announced today the successful opposition of a ...

CAMBRIDGE, Mass. & CARLSBAD, Calif.-- --Jun 24, 2008 - Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals Inc. inked its third significant deal of the year, signing an exclusive alliance agreement to develop and commercialize ALN-RSV01, its lead RNAi therapeutic for the treatment of ...

Alnylam Pharmaceuticals Ties Up with Kyowa Hakko Kogyo Co., Ltd. on Respiratory Drug in Asia; Alnylam to Receive $15M Upfront Payment and $78M Milestone Payments 6/19/2008 CAMBRIDGE, Mass.

RNAi specialist, Japanese drugmaker team up for Asian market in a deal worth up to $1 billion Rick Mullin U.S.-based Alnylam Pharmaceuticals and Japan's Takeda Pharmaceutical have formed an alliance to develop ...

CAMBRIDGE, Mass. - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced the closing of its investment in and completion of its expanded agreement with Tekmira Pharmaceuticals ...

Mergers for Alnylam Create Risk Posted Fri May 30, 04:47 pm ET Posted By: Grant Zeng, CFA Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi ...

Isis Pharmaceuticals, Inc. announced today that it will receive $4.6 million dollars from Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals and Takeda Pharmaceutical Co. Ltd. have formed a strategic platform alliance in RNAi therapeutics in the fields of oncology and metabolic disease with the option to expand to additional ...

“I think there's certainly a resurgence in the interest in (chemical drugs)”

Mass High Tech: The Journal of New England Technology - by Ryan Mcbride Mass High Tech Sandie Allen Avila Therapeutics’ band of doctorate brothers include, from left, Russell Petter, co-founder and CSO ... via Mass High Tech

THE REGION Alnylam Pharmaceuticals Inc.'s share rose 9 percent after the Cambridge biotechnology company posted a smaller-than-expected first-quarter loss and strong revenue growth. via Boston Globe

May 12, 2008 - Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that management will present a company overview at the Rodman & Renshaw 5th Annual Global Healthcare ... via Med Ad News

Swiss pharmaceutical giant Novartis AG has upped its ownership stake in Alnylam Pharmaceuticals Inc. via Boston Business Journal

Amylin Pharmaceuticals Ammending Pact with Eli Lilly Concerning U.S. Marketing; Gilead Sciences CEO John Martin Takes on Additional Duties as Board Chairman; Novartis to Buy Another 214K Addtional Unregistered ... via ClipSyndicate

Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, announced today that Novartis has elected to fully exercise its current right to purchase 213,888 unregistered shares of Alnylam's common ... via BioSpace

Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that it will report financial results for the first - 05/02/2008 - 04:00 PM MINNEAPOLIS-- --Urologix , Inc. via Business Wire

“This new study continues to expand Alnylam's scientific leadership in the field of RNAi research as it represents continued understanding and refinement of our discovery process where - drug-like' properties of siRNAs can be readily achieved”

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced the publication of a study in the Journal of Interferon & Cytokine Research by scientists at Alnylam Europe , and collaborators, ... via BioResearch Online